Featured Research

from universities, journals, and other organizations

Advanced pancreatic cancer: Phase I drug study underway

Date:
June 3, 2014
Source:
University of Illinois at Chicago
Summary:
A clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer is underway. Pancreatic ductal carcinoma has a five-year survival rate of less than 5 percent and is the fourth-leading cause of cancer death in the U.S., claiming nearly 40,000 lives each year. Scientists have made some progress in the last decade to understand the biology of the disease at the cellular level, but advances in clinical outcomes have not kept pace.

Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

Pancreatic ductal carcinoma has a five-year survival rate of less than 5 percent and is the fourth-leading cause of cancer death in the U.S., claiming nearly 40,000 lives each year.

Scientists have made some progress in the last decade to understand the biology of the disease at the cellular level, but advances in clinical outcomes have not kept pace.

"There is an urgent and unmet need for effective treatments for patients with advanced pancreatic cancer after first-line chemotherapy fails," said Dr. Neeta Venepalli, UIC assistant professor of hematology and principal investigator of the study.

Patients in the phase 1 study will be given three drugs that are thought to attack the cancer cells in different ways. One, gemcitabine, is an FDA-approved chemotherapy drug that works by slowing or stopping the growth of tumors. It has been the standard treatment for advanced pancreatic cancer for the past decade.

A second drug, a monoclonal antibody that recognizes a protein called mucin 1 that prevents the death of cancer cells and is overabundant in pancreatic ductal carcinoma, is given to patients to stimulate an immune response. The antibody also attracts the third drug, Imprime PGG, which travels to the tumor site to activate an immune response and kill targeted cancer cells.

"Our phase 1 trial combines gemcitabine with two novel cancer immunotherapies -- a regimen that has not been tried before," said Venepalli, a member of the UI Cancer Center.

"We are optimistic and excited about providing a new approach to treating this devastating disease."

The study will evaluate the drug combination to determine the highest dose of the monoclonal antibody that can be tolerated without unacceptable side effects.


Story Source:

The above story is based on materials provided by University of Illinois at Chicago. The original article was written by Sherri McGinnis Gonzαlez. Note: Materials may be edited for content and length.


Cite This Page:

University of Illinois at Chicago. "Advanced pancreatic cancer: Phase I drug study underway." ScienceDaily. ScienceDaily, 3 June 2014. <www.sciencedaily.com/releases/2014/06/140603162016.htm>.
University of Illinois at Chicago. (2014, June 3). Advanced pancreatic cancer: Phase I drug study underway. ScienceDaily. Retrieved September 15, 2014 from www.sciencedaily.com/releases/2014/06/140603162016.htm
University of Illinois at Chicago. "Advanced pancreatic cancer: Phase I drug study underway." ScienceDaily. www.sciencedaily.com/releases/2014/06/140603162016.htm (accessed September 15, 2014).

Share This



More Health & Medicine News

Monday, September 15, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) — The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) — A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) — The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) — The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins